ATE451118T1 - Von pigmentepithel stammender faktor zur hemmug der glialzellen-proliferation - Google Patents

Von pigmentepithel stammender faktor zur hemmug der glialzellen-proliferation

Info

Publication number
ATE451118T1
ATE451118T1 AT07007638T AT07007638T ATE451118T1 AT E451118 T1 ATE451118 T1 AT E451118T1 AT 07007638 T AT07007638 T AT 07007638T AT 07007638 T AT07007638 T AT 07007638T AT E451118 T1 ATE451118 T1 AT E451118T1
Authority
AT
Austria
Prior art keywords
pedf
rpedf
cell proliferation
effect
glial cell
Prior art date
Application number
AT07007638T
Other languages
English (en)
Inventor
Gerald J Chader
Sofia Patricia Becerra
Joan P Schwartz
Takayuki Taniwaki
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/257,963 external-priority patent/US5840686A/en
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE451118T1 publication Critical patent/ATE451118T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
AT07007638T 1994-06-07 1995-06-06 Von pigmentepithel stammender faktor zur hemmug der glialzellen-proliferation ATE451118T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/257,963 US5840686A (en) 1992-09-24 1994-06-07 Pigment epithelium-derived factor: characterization of its novel biological activity and sequences encoding and expressing the protein and methods of use
US08/367,841 US6319687B1 (en) 1992-09-24 1994-12-30 Pigment epithelium-derived factor: characterization, genomic organization and sequence of PEDF gene

Publications (1)

Publication Number Publication Date
ATE451118T1 true ATE451118T1 (de) 2009-12-15

Family

ID=26946312

Family Applications (2)

Application Number Title Priority Date Filing Date
AT07007638T ATE451118T1 (de) 1994-06-07 1995-06-06 Von pigmentepithel stammender faktor zur hemmug der glialzellen-proliferation
AT95922988T ATE359810T1 (de) 1994-06-07 1995-06-06 Faktor aus pigmentiertem epithel (pedf) charakterisierung, genomische organisation und sequenz des pedf gens

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT95922988T ATE359810T1 (de) 1994-06-07 1995-06-06 Faktor aus pigmentiertem epithel (pedf) charakterisierung, genomische organisation und sequenz des pedf gens

Country Status (9)

Country Link
US (3) US6319687B1 (de)
EP (2) EP0765169B1 (de)
JP (3) JPH10504705A (de)
AT (2) ATE451118T1 (de)
AU (1) AU710141B2 (de)
CA (2) CA2190365C (de)
DE (2) DE69536028D1 (de)
ES (1) ES2288300T3 (de)
WO (1) WO1995033480A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856097A (en) 1992-03-04 1999-01-05 The Regents Of The University Of California Comparative genomic hybridization (CGH)
US6451763B1 (en) * 1992-06-04 2002-09-17 The United States Of America As Represented By The Department Of Health And Human Services Retinal pigmented epithelium derived neurotrophic factor and methods of use
US6319687B1 (en) * 1992-09-24 2001-11-20 The United States Of America As Represented By The Department Of Health And Human Services Pigment epithelium-derived factor: characterization, genomic organization and sequence of PEDF gene
US7455964B1 (en) * 1996-07-15 2008-11-25 The Hospital For Sick Children Genes from the 20q13 amplicon and their uses
US7049424B2 (en) 1996-07-15 2006-05-23 The Regents Of The University Of California Genes from the 20Q13 amplicon and their uses
US5801021A (en) 1995-10-20 1998-09-01 The Regents Of The University Of California Amplifications of chromosomal region 20q13 as a prognostic indicator in breast cancer
WO1998024812A2 (en) * 1996-12-03 1998-06-11 Neurocrine Biosciences, Inc. A6la5a12 polypeptides and polynucleotides and methods of use therefor
CA2276183C (en) 1996-12-31 2009-06-09 Antioxidant Pharmaceuticals Corporation Pharmaceutical preparations of glutathione and methods of administration thereof
EP1015014A4 (de) 1997-07-23 2005-01-05 Univ Northwestern Verfahren und Zusammenstellungen zur Inhibierung der Angiogenese
US7105496B2 (en) 1998-07-23 2006-09-12 Northwestern University Methods and compositions for inhibiting angiogenesis
US6797691B1 (en) 1997-07-23 2004-09-28 Northwestern University Methods and compositions for inhibiting angiogenesis
AU9303498A (en) * 1997-09-02 1999-03-22 Medical College Of Georgia Research Institute, Inc. Human aminopeptidase p gene
CA2368376A1 (en) * 1999-03-26 2000-10-05 Human Genome Sciences, Inc. 50 human secreted proteins
JP2003502053A (ja) * 1999-06-11 2003-01-21 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ４９個のヒト分泌タンパク質
US6821775B1 (en) 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
AU780634C (en) * 2000-02-11 2006-02-23 Genvec, Inc. Gene Therapy for treating ocular-related disorders
DE60136444D1 (de) * 2000-02-23 2008-12-18 Univ Northwestern Pharmazeutische zusammensetzung zur angiogenese-hemmung mittels eines pedf-fragmentes
WO2001063293A2 (en) * 2000-02-24 2001-08-30 Oxford Glycosciences (Uk) Ltd. Diagnosis and treatment of schizophrenia
IL147444A0 (en) * 2002-01-03 2002-08-14 Yeda Res & Dev Process for the production of pigment epithelium derived factor (pedf) from human blood and uses thereof
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
CA2493849A1 (en) * 2002-07-12 2004-01-22 University Of Washington Methods and systems for extended in vitro culture of neuronal cells
US20040161423A1 (en) * 2002-07-18 2004-08-19 Sanjeev Kumar (Mendiratta) Polymer modified anti-angiogenic serpins
US20050222031A1 (en) * 2004-03-19 2005-10-06 Yamagishi Sho-Ichi Method for preventing or treating malignant melanoma
WO2006046584A1 (ja) * 2004-10-26 2006-05-04 Santen Pharmaceutical Co., Ltd. 視細胞障害治療剤
WO2006054278A2 (en) 2004-11-16 2006-05-26 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Variants of pigment epithelium derived factor and uses thereof
EP2314614B1 (de) * 2005-02-28 2015-11-25 Sangamo BioSciences, Inc. Anti-angiogene Verfahren und Zusammensetzungen
GB0516058D0 (en) * 2005-08-04 2005-09-14 Oxford Genome Sciences Uk Ltd New protein isoforms and uses thereof
US8106010B2 (en) * 2005-11-14 2012-01-31 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Variants of pigment epithelium derived factor and uses thereof
EP1986676A4 (de) * 2006-02-15 2009-11-04 Univ Yale Inc Zusammensetzungen und verfahren zur verwendung von pedf- (von pigmenthaltigem epithel abgeleiteter faktor) peptidfragmenten
ITTV20080039A1 (it) * 2008-03-06 2009-09-07 Alpinestars Research Srl Collare di protezione in particolare per guidatori di motoveicoli
CA2776748A1 (en) * 2009-10-08 2011-04-14 Neurotech Usa, Inc. Use of pedf in an encapsulated cell-based delivery system
US9938328B2 (en) * 2012-09-17 2018-04-10 Mackay Memorial Hospital Use of PEDF-derived polypeptides for treating alopecia and/or hair depigmentation
US9611314B2 (en) 2013-09-13 2017-04-04 The Penn State Research Foundation Functional peptide analogs of PEDF
JP6522063B2 (ja) * 2017-08-10 2019-05-29 マクカイ メモリアル ホスピタル 脱毛症及び／又は毛髪色素脱失を治療するためのｐｅｄｆ由来のポリペプチドの使用
KR101998155B1 (ko) * 2017-09-22 2019-07-10 (주)케어젠 혈관신생 억제용 펩타이드 및 이의 용도

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1700691A (en) 1927-03-08 1929-01-29 Lilly Co Eli Optic-nerve and retina extract and process of making it
FR2461002A1 (fr) 1979-07-13 1981-01-30 Inst Nat Sante Rech Med Procede pour stimuler la croissance des cellules d'epiderme humain et produits faisant application dudit procede
US4477435A (en) 1981-05-19 1984-10-16 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for regenerating corneal epithelium
US4770877A (en) 1982-08-03 1988-09-13 Boston Biomedical Research Institute Isolation of a high molecular weight aortic endothelial cell growth inhibitor
US4534967A (en) 1982-08-03 1985-08-13 Boston Biomedical Research Institute Cell proliferation inhibitor and method of preparation
US4818542A (en) * 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
AU590872B2 (en) 1985-02-26 1989-11-23 Johns Hopkins University, The Neovascularization inhibitors and methods for their production and use
US5244902A (en) * 1989-08-21 1993-09-14 Beth Israel Hospital Association Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses
EP1415994A1 (de) * 1992-06-04 2004-05-06 The University Of Southern California Neurothroper Faktor aus pigmentiertem retinalem Epithelgewebe
US5840686A (en) * 1992-09-24 1998-11-24 The United States Of America As Represented By The Department Of Health And Human Services Pigment epithelium-derived factor: characterization of its novel biological activity and sequences encoding and expressing the protein and methods of use
US6451763B1 (en) * 1992-06-04 2002-09-17 The United States Of America As Represented By The Department Of Health And Human Services Retinal pigmented epithelium derived neurotrophic factor and methods of use
US6319687B1 (en) * 1992-09-24 2001-11-20 The United States Of America As Represented By The Department Of Health And Human Services Pigment epithelium-derived factor: characterization, genomic organization and sequence of PEDF gene
FI104514B (fi) * 1997-02-18 2000-02-15 Safematic Oy Sovitelma kiertovoitelujärjestelmän yhteydessä
US6319781B1 (en) * 2001-02-28 2001-11-20 Macronix International Co., Ltd. Method of fabricating self-aligned multilevel mask ROM

Also Published As

Publication number Publication date
JP2006149405A (ja) 2006-06-15
ES2288300T3 (es) 2008-01-01
DE69536028D1 (de) 2010-01-21
DE69535467T2 (de) 2008-01-03
JP2009153517A (ja) 2009-07-16
ATE359810T1 (de) 2007-05-15
CA2704083C (en) 2013-07-30
EP0765169B1 (de) 2007-04-18
JP5108797B2 (ja) 2012-12-26
AU710141B2 (en) 1999-09-16
CA2190365C (en) 2010-08-03
CA2704083A1 (en) 1995-12-14
US6319687B1 (en) 2001-11-20
US7179621B1 (en) 2007-02-20
EP1864678A1 (de) 2007-12-12
WO1995033480A1 (en) 1995-12-14
EP0765169A1 (de) 1997-04-02
EP1864678B1 (de) 2009-12-09
CA2190365A1 (en) 1995-12-14
AU2768195A (en) 1996-01-04
US20060008900A1 (en) 2006-01-12
JPH10504705A (ja) 1998-05-12
DE69535467D1 (de) 2007-05-31

Similar Documents

Publication Publication Date Title
ATE451118T1 (de) Von pigmentepithel stammender faktor zur hemmug der glialzellen-proliferation
ATE284954T1 (de) Hyaluronan synthase gen und seine verwendung
DE3856265D1 (de) Varianten des pankreatischen Rinder-Trypsininhibitors, deren Herstellung und Verwendung
DE3585210D1 (de) Fuer kolonie stimulierenden faktor kodierende dns, dadurch kodiertes peptid, diese dns enthaltende vektoren und transformierte wirte und herstellung derselben.
PT101297A (pt) Factores mitogenicos gliais, sua preparacao e utilizacao
DE69435038D1 (de) Aktivin rezeptor-ähnliche kinase (alk), gehörend zur tgf rezeptorfamilie und/oder zur bmp rezeptorfamilie
ES2218872T3 (es) Polipeptido 10 de tipo citoquina de mamifero.
BR9508019B1 (pt) Ácido nuclÉico, vetor de expressço, cÉlula hospedeira e composiÇço farmacÊutica.
NO179412C (no) Hybrid DNA-molekyl som koder for fibronektinbindende protein, mikroorganismer inneholdende slike DNA-molekyler samt fremgangsmåte ved fremstilling av slikt protein
CA2287521A1 (en) Human recombinant beta-interferon with improved solubility
DK0666914T3 (da) Hidtil ukendt P-selectin-ligandprotein
MX9203645A (es) Nuevos interferones de humano y proceso biotecnologico para su produccion.
ATE424410T1 (de) Interleukin-19.
DE69013811D1 (de) Verfahren zur Herstellung von antiviralem Protein unter Benützung von E.coli-Transformant, das Gen, das für dieses Protein kodiert und E.coli-Vektor benützt in diesem Verfahren.
NO177570C (no) Fremgangsmåte ved fremstilling av peptider med fibronektinbindende egenskaper, mikroorganisme og DNA-sekvens som koder for peptider med fibronektinbindende egenskaper
DE68902192T2 (de) Ethylenthioharnstoff enthaltende zusammensetzungen zur herstellung von verschleissfesten, stromlos abgeschiedenen nickel-borueberzuegen.
WO2002074956A3 (en) Dopaminergic neuronal survival-promoting factors and uses thereof
ES2170144T3 (es) Variantes que no se empalman de gp350/220.
DE3783145D1 (de) Rekombinantes dns-plasmid zur herstellung von xanthangummi.
DE3584029D1 (de) Expressionsvektoren, dns-fragmente, peptide, wirte und verfahren zur herstellung von peptiden.
NO178870C (no) Fremgangsmåte for fremstilling av modifisert Eglin B eller C samt DNA, ekspresjonsvektor og vertsmikroorganisme
DE3750571T2 (de) Herstellung von rekombinantem, menschlichem PSTI.
NO874704L (no) Minaktivin fremstilt ved rekombinant dna-teknikk.
EP0288057A3 (de) Des-19-Leucin,20-Glutamin,21-Threonin,22-Tyrosin-Calcitonin
DE69220259D1 (de) Verfahren zur Herstellung von menschlichem NGF-2

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties